Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03

December 22, 2019
Sponsored Content

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.

Related Content:

CURE TV
Kathy Ireland Joins the National Pediatric Cancer Foundation’s ‘Team 43’ to Raise Funds and Awareness
How Treating Myeloma is About Extending Remissions and Making it ‘Livable’
Myeloma Therapies Create an ‘Optimistic Picture’ for Patients’ Futures